Tailoring Combination Strategies to Address Disease Heterogeneity & Improve Therapeutic Outcomes

  • Evaluating how distinct metabolic and fibrotic disease drivers contribute to patient heterogeneity to identify high-value responder populations, enabling more targeted development strategies and improving therapeutic efficacy
  • Assessing the potential of combination approaches that address complementary disease mechanisms to overcome variability in treatment response, enabling enhanced clinical benefit and improving outcomes across broader patient populations
  • Leveraging clinical and biological insights to match therapies to patients most likely to benefit, improving trial precision and supporting the development of more effective and differentiated treatment paradigms